Page 92 - Read Online

Skorupan et al. J Cancer Metastasis Treat 2023;9:5 https://dx.doi.org/10.20517/2394-4722.2022.106 Page 21 of 26

Science 2008;321:1801-6. DOI PubMed PMC
27. Luo J. KRAS mutation in pancreatic cancer. Semin Oncol 2021;48:10-8. DOI PubMed PMC
28. Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic
adenocarcinoma. J Clin Oncol 2015;33:3124-9. DOI PubMed
29. Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J
Clin Oncol 2017;35:3382-90. DOI PubMed PMC
30. O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without
veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020;38:1378-88. DOI
PubMed PMC
31. Fogelman D, Sugar EA, Oliver G, et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer
Chemother Pharmacol 2015;76:489-98. DOI PubMed PMC
32. Reiss KA, Yu S, Judy R, Symecko H, Nathanson KL, Domchek SM. Retrospective survival analysis of patients with advanced
pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations. JCO Precis Oncol 2018;2:1-9. DOI
33. Yu S, Agarwal P, Mamtani R, et al. Retrospective survival analysis of patients with resected pancreatic ductal adenocarcinoma and a
germline BRCA or PALB2 mutation. JCO Precis Oncol 2019;3:1-11. DOI
34. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med
2019;381:317-27. DOI
35. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531:47-52.
DOI
36. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Nat Med 2011;17:500-3. DOI PubMed PMC
37. Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic
ductal adenocarcinoma. Nat Genet 2015;47:1168-78. DOI PubMed PMC
38. Topham JT, Karasinska JM, Lee MKC, et al. Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate
clinical and molecular characteristics. Clin Cancer Res 2021;27:150-7. DOI PubMed
39. Hayashi A, Fan J, Chen R, et al. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal
adenocarcinoma. Nat Cancer 2020;1:59-74. DOI PubMed PMC
40. Chan-Seng-Yue M, Kim JC, Wilson GW, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during
tumor evolution. Nat Genet 2020;52:231-40. DOI
41. Raghavan S, Winter PS, Navia AW, et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell
2021;184:6119-6137.e26. DOI PubMed PMC
42. Porter RL, Magnus NK, Thapar V, Morris R, Szabolcs A, Neyaz A, Kulkarni AS, Tai E, Chougule A, Hillis A. Epithelial to
mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA
2019;116:26835-45. DOI PubMed PMC
43. Madura JA, Jarman BT, Doherty MG, Yum MN, Howard TJ. Adenosquamous carcinoma of the pancreas. Arch Surg 1999;134:599-
603. DOI PubMed
44. Board WCoTE. Digestive system tumors. Lyon, France; 2019.
45. Kardon DE, Thompson LD, Przygodzki RM, Heffess CS. Adenosquamous carcinoma of the pancreas: a clinicopathologic series of
25 cases. Mod Pathol 2001;14:443-51. DOI PubMed
46. Murakami Y, Yokoyama T, Yokoyama Y, et al. Adenosquamous carcinoma of the pancreas: preoperative diagnosis and molecular
alterations. J Gastroenterol 2003;38:1171-5. DOI PubMed
47. Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol
2019;16:207-20. DOI PubMed
48. Olson MT, Siddiqui MT, Ali SZ. The differential diagnosis of squamous cells in pancreatic aspirates: from contamination to
adenosquamous carcinoma. Acta Cytol 2013;57:139-46. DOI PubMed
49. Voong KR, Davison J, Pawlik TM, et al. Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of
adjuvant chemotherapy and radiation in 38 patients. Hum Pathol 2010;41:113-22. DOI PubMed PMC
50. Ito T, Sugiura T, Okamura Y, et al. Long-term outcomes after an aggressive resection of adenosquamous carcinoma of the pancreas.
Surg Today 2019;49:809-19. DOI PubMed
51. Lee SM, Sung CO. PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of
56 lesions. Pancreatology 2021;21:920-7. DOI PubMed
52. Viswanathan K, Rao R. Pancreatic ductal adenocarcinoma and its variants. In: Pancreas and biliary tract cytohistology. Cham:
Springer International Publishing; 2019. pp. 95-145. DOI
53. Brody JR, Costantino CL, Potoczek M, et al. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular
alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol 2009;22:651-9. DOI PubMed
54. Taniwaki S, Hisaka T, Sakai H, et al. Sarcomatous component in pancreatic adenosquamous carcinoma: a clinicopathological series
of 7 cases. Anticancer Res 2019;39:4575-80. DOI PubMed
55. Boecker W, Tiemann K, Boecker J, et al. Cellular organization and histogenesis of adenosquamous carcinoma of the pancreas:
evidence supporting the squamous metaplasia concept. Histochem Cell Biol 2020;154:97-105. DOI PubMed PMC